Trade Summary

Yesterday, Campbell David Alan, serving as Pres, CEO at Janux Therapeutics, Inc. (JANX), sold 8,072 shares at $13.73 per share, for a total transaction value of $110,829.00. Following this transaction, Campbell David Alan now holds 381,582 shares of JANX.

This sale represents a 2.00% decrease in Campbell David Alan's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, January 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, January 2, 2026, meaning the disclosure happened on the same day as the trade.

Janux Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.